Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
A
065660
vs
K
KOSPI 200
Over the past 12 months, Anterogen Co Ltd has underperformed KOSPI 200, delivering a return of -39% compared to KOSPI 200's +52% growth.
Stocks Performance
065660 vs KOSPI 200
Performance Gap
065660 vs KOSPI 200
Performance By Year
065660 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Anterogen Co Ltd
Glance View
Anterogen is a South Korean regenerative medicine company that develops and sells cell-based therapies, especially stem cell treatments made from human tissue. Its best-known products are used in hospitals for difficult conditions such as inflammatory and tissue-repair diseases, where standard drugs may not be enough. The company makes money by selling these therapies to medical institutions that administer them to patients. It also works with healthcare partners on development, manufacturing, and regulatory support for cell therapy products, which helps it move treatments from the lab into clinical use. What makes Anterogen different is that it sits at the intersection of drug development and advanced manufacturing. Instead of selling a broad range of medicines, it focuses on a narrow class of living-cell therapies that are harder to produce, regulate, and deliver than ordinary pharmaceuticals, so its value comes from specialized scientific know-how and medical approvals.